Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer

被引：0
|
作者：
Schilsky, R. L.
Geary, D.
Skoog, L.
Desai, A.
Valickas, J.
Masson, E.
Laurent, D.
Pendowski, C.
Vokes, E.
Ratain, M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Novartis Oncol, E Hanover, NJ USA
[3] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3595
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas.
    George, D
    Jonasch, E
    Hart, L
    Lentz, J
    Parker, K
    Henry, A
    Pfister, C
    Dugan, M
    Laurent, D
    Clark, J
    Kaelin, WG
    Oh, W
    Kantoff, P
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3764S - 3764S
  • [2] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E. G.
    Younger, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B. P.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E.
    Foster, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sharma, Sunil
    Freeman, Burgess
    Turner, Jeanette
    Symanowski, James
    Manno, Phillip
    Berg, William
    Vogelzang, Nicholas
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 63 - 65
  • [5] Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
    Speca, J. C.
    Mears, A. L.
    Creel, P. A.
    Yenser, S. E.
    Bendell, J. C.
    Morse, M. A.
    Hurwitz, H. I.
    Armstrong, A. J.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sunil Sharma
    Burgess Freeman
    Jeanette Turner
    James Symanowski
    Phillip Manno
    William Berg
    Nicholas Vogelzang
    Investigational New Drugs, 2009, 27 : 63 - 65
  • [7] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMA
    Deboer, Rebecca
    Grimm, Sean
    Chandler, James
    Gallot, Lilia
    Kennedy, Shannon
    Burns, Kimberly
    Rice, Laurie
    Cabreza, Czarina
    Muro, Kenji
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [8] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMAS
    Raizer, Jeffrey
    Grimm, Sean
    Chandler, James
    Muro, Kenji
    Rice, Laurie
    McCarthy, Katie
    Mrugala, Maciej
    Johnston, Sandra K.
    Chamberlain, Marc
    NEURO-ONCOLOGY, 2010, 12 : 50 - 50
  • [9] Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)
    Drevs, J
    Mross, K
    Reusch, P
    Peng, B
    Ball, H
    Henry, A
    Laurent, D
    Dugan, M
    Marme, D
    Unger, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S283
  • [10] The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy
    Banerjee, S. N.
    Thornhill, A.
    Evans, D. B.
    Littlewood-Evans, A. J.
    Dowsett, M.
    Martin, L-A
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S8 - S8
12345